Umbralisib HCl (also known as TGR-1202; RP5264; trade name Ukoniq), the hydrochloride salt of Umbralisib, is an orally bioavailable PI3Kδ inhibitor that has gained FDA approval in 2021for treating marginal zone lymphoma and follicular lymphoma.

Pictilisib (also called GDC-0941, Pictrelisib, RG-7321 and GNE-0941) is a potent and orally bioavailable inhibitor of PI3Kα/δ (class I phosphatidylinositol 3 kinase) with IC50 of 3 nM in cell-free assays.

Dactolisib tosylate (formerly also known as NVP-BEZ235 tosylate and BEZ-235 tosylate) is an ATP-competitive and dual inhibitor of PI3K (phosphatidylinositol 3-kinase) and mTOR for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively.

Alpelisib (formerly also known as BLY719; trade name: Piqray) is a novel, potent, newly approved, orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with antineoplastic activity.

Duvoglustat hydrochloride (1-Deoxynojirimycin; AT-2220; Moranoline; deoxynojirimycin; DNJ) is a novel and potent alpha-glucosidase inhibitor found in mulberry leaves and has antihyperglycemic, anti-obesity, and antiviral activities.

Tenalisib R Enantiomer is the R-isomer of Tenalisib (also known as RP-6530).

TG100713 is a novel and potent pan-PI3K (phosphatidylinositol 3-kinase) inhibitor with potential anti-inflammatory activity.

SAR260301 is potent, orally bioavailable and selective Class I phosphatidylinositol-3-kinase (PI3K)β specific inhibitor with an IC50 of 52 nM for PI3Kβ.

IC-87114 is a novel, potent, selective and ATP-competitive PI3Kδ inhibitor (p110delta-selective) with potential anticancer activity.

AS-605240 is a novel, potent, orally bioactive and ATP-competitive inhibitor of PI3-kinase γ (PI3Kγ) with potential anti-inflammatory activity.